Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat for primary aldosteronism
2025-520740-16-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in primary aldosteronism (PA) comparing Baxdrostat with Placebo (2 arms). Primary endpoints: Change from baseline in seated systolic blood pressure at Week 8 and Normalization of renin at Week 8 in participants with dysregulated renin at baseline. Planned start Sep 2025; status: authorised.
02
Drugs
baxdrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on 2025-520740-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520740-16-00.